Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma

Medulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells...

Full description

Bibliographic Details
Main Authors: Jessica Buck, Patrick J. C. Dyer, Hilary Hii, Brooke Carline, Mani Kuchibhotla, Jacob Byrne, Meegan Howlett, Jacqueline Whitehouse, Martin A. Ebert, Kerrie L. McDonald, Nicholas G. Gottardo, Raelene Endersby
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Molecular Biosciences
Subjects:
Medulloblastoma
radiotherapy
veliparib
DNA repair
poly(ADP-ribose) polymerase
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.633344/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.633344/full

Similar Items